PEGASUS Clinical Study of AMX0035 in Alzheimer’s Disease


The Amylyx PEGASUS Alzheimer’s disease phase 2 clinical trial will enroll 100 patients at sites across the country in a double-blind protocol to test a combinatorial therapy. AMX0035 is composed of two known compounds that together address endoplasmic reticulum and mitochondrial stress, both of which have been implicated in neuronal death and degradation. The trial is enrolling patients who already are experiencing mild cognitive impairment or early dementia. The results from the study are anticipated in 2020.

Funding to Date



Clinical Trials, Drug Development